Yang Yiping, Huang Ching-Tai, Huang Xiaopei, Pardoll Drew M
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Nat Immunol. 2004 May;5(5):508-15. doi: 10.1038/ni1059. Epub 2004 Apr 4.
One chief barrier to cancer immunotherapy is tumor-specific T cell tolerance. Here we compared the ability of hemagglutinin (HA)-encoding recombinant viruses versus 'HA-loaded' dendritic cells to reverse HA-specific CD8 tolerance and to protect mice from tumor challenge. Both vaccines were comparable in activating naive HA-specific CD8(+) T cells. However, in circumstances of established tolerance, viral vaccines could break CD8 tolerance in the presence of CD4(+)CD25(+) regulatory T cells, whereas dendritic cell-based vaccines achieved this only after removal of regulatory T cells or the coadministration of a Toll-like receptor (TLR) ligand or irrelevant virus. These results demonstrate that virus provides TLR signals required for bypassing regulatory T cell-mediated tolerance and emphasize the importance of persistent TLR signals for immunotherapy in the setting of established tolerance.
癌症免疫疗法的一个主要障碍是肿瘤特异性T细胞耐受性。在此,我们比较了编码血凝素(HA)的重组病毒与“负载HA”的树突状细胞在逆转HA特异性CD8耐受性以及保护小鼠免受肿瘤攻击方面的能力。两种疫苗在激活幼稚HA特异性CD8(+) T细胞方面具有可比性。然而,在已建立耐受性的情况下,病毒疫苗能够在CD4(+)CD25(+)调节性T细胞存在的情况下打破CD8耐受性,而基于树突状细胞的疫苗只有在去除调节性T细胞或同时给予Toll样受体(TLR)配体或无关病毒后才能做到这一点。这些结果表明,病毒提供了绕过调节性T细胞介导的耐受性所需的TLR信号,并强调了持续的TLR信号在已建立耐受性情况下免疫治疗中的重要性。